Clichy

• Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced Ended
  2023-506657-38-00 5 2019-10-02 Biliary Tract Carcinoma
• A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with lo … Ended
  2023-509053-32-00 5 2019-07-17 Locoregional Hepatocellular Carcinoma (HCC)
• Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su … Ended
  2022-501971-24-00 5 2019-05-20 Adjuvant treatment of HCC
• EASE SBS 2 (Evaluation of the efficacy and safety of Glepaglutide in the treatment of short bowel syndrome) (SBS) Ended
  2024-513374-22-00 5 2019-04-30 Short Bowel Syndrome
• Acute-On-Chronic Liver Failure (ACLF) at High Risk of Hospital Mortality Ended
  2022-502187-20-00 5 2019-04-11 Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected eith
• A study on the safety, efficacy and immune response following sequential treatment with an anti-sense oligonucleotide against chronic Hepati … Ended
  2024-512352-38-00 4 2019-03-28 Hepatitis B, Chronic
• A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin … Ended
  2024-513513-12-00 5 2019-01-06 Cholangiocarcinoma
• A study to investigate the safety and tolerability of dostarlimab in adult participants with chronic HBV infection on nucleos(t)ide analogue … Ended
  2023-509027-41-00 3 Hepatitis B, Chronic
• A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 … Expired
  2022-502724-46-00 9 Chronic Hepatitis B Infection

Showing 169–177 of 177 trials